# Study of AggreGuide A-100 (ADP) Assay

> **NCT03111420** · NA · COMPLETED · sponsor: **Aggredyne, Inc.** · enrollment: 280 (actual)

## Conditions studied

- Risk Factor, Cardiovascular
- Platelet Dysfunction Due to Drugs

## Interventions

- **DRUG:** P2Y12 inhibitor
- **DEVICE:** Platelet function test

## Key facts

- **NCT ID:** NCT03111420
- **Lead sponsor:** Aggredyne, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-09
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03111420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03111420, "Study of AggreGuide A-100 (ADP) Assay". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03111420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*